Τίτλος:
Sequential treatment with sorafenib and sunitinib in metastatic renal
cell carcinoma: clinical outcomes from a retrospective clinical study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Sorafenib and sunitinib are inhibitors of receptor protein tyrosine
kinases (TKIs) and are approved for the treatment of metastatic renal
cell carcinoma (mRCC). Although the mTOR inhibitor everolimus is
effective for the treatment of patients who have failed TKI therapy, it
is important to consider all available treatment options before
switching therapy mode of action. Herein, we report outcomes in patients
with mRCC switched to sorafenib following disease progression on
sunitinib treatment. The medical records of 35 patients treated between
November 2006 and November 2009 at two large referral centers in Greece
were retrospectively analyzed for time-to-progression (TTP), overall
survival (OS), and tolerability of sorafenib after sunitinib. Median TTP
and OS on sorafenib were 4.9 and 11.5 months, respectively. Among 33
patients evaluable for tumor response, three had a partial response and
17 achieved disease stabilization (objective response rate 8.5%; total
clinical benefit rate 57%). Sorafenib was well tolerated, with mostly
grade 1/2 adverse events and no treatment-related deaths. Sorafenib was
effective and well tolerated in this group of patients. The TTP with
sorafenib following sunitinib was comparable to outcomes reported
previously, providing further support that TKIs should be used in
sequence before switching to an mTOR inhibitor.
Συγγραφείς:
Kontovinis, Loukas
Laschos, Konstantinos
Karadimou, Alexandra
and Andreadis, Charalambos
Bamias, Aristotelis
Paraskevopoulos,
Panagiotis
Dimopoulos, Meletios
Papazisis, Konstantinos
Περιοδικό:
Medical Oncology
Εκδότης:
Humana Press Inc.
Λέξεις-κλειδιά:
Renal cell cancer; Sorafenib; Sunitinib; Second-line; Sequencing;
Sequential use; Tyrosine kinase inhibitor
DOI:
10.1007/s12032-010-9815-6
